Scott Morrison, a retired Ernst & Young Partner, was appointed to the board of directors at Audentes Therapeutics and Global Blood Therapeutics.Watch Full Movie Online Streaming Online and Download
Audentes Therapeutics is a San Francisco-based biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. Morrison will serve as chairman of the Audentes’ audit committee. The firm recently filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). There were no pricing details given in the filing, but the offering is valued up to USD86.25 million.
Based in San Francisco, Global Blood Therapeutics is a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs. The firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a clinical trial.
With 35 years of financial experience, Morrison served as Ernst & Young U.S. Life Sciences Leader from 2002 to December 2015. He has held roles on the boards of directors of numerous life sciences industry organizations. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has also served on the audit committee since 2002. He previously served on the boards of directors of the Life Sciences Foundation, the Bay Area Biosciences Association and the Emerging Companies Section of the Biotechnology Industry Organization.